0
0
New Delhi, Aug 13: A groundbreaking study from the University of California, Irvine, reveals a significant disparity in Alzheimer’s disease progression between men and women with Down syndrome. The research, published in the journal Alzheimer’s & Dementia, found that women with Down syndrome exhibit more advanced signs of the disease than their male counterparts, despite receiving a diagnosis at the same average age.
Key Findings and Biological Differences
The study identified higher levels of key Alzheimer’s proteins—beta amyloid and phosphorylated tau—in the brains of women with Down syndrome. These proteins, which form plaques and tangles, are hallmarks of the disease. The differences were particularly prominent in the occipital lobe, a brain region also known to be affected in women with late-onset Alzheimer’s in the general population.
Lead author Elizabeth Andrews highlighted the importance of these findings, stating, “Understanding selective vulnerabilities within the brain and how these differ in women versus men will help us better navigate treatment outcomes.” The research suggests that women with Down syndrome may be further along in the disease’s progression at the point of diagnosis.
Implications for Research and Treatment
This discovery has critical implications for the future of Alzheimer’s research and clinical practice. People with Down syndrome are genetically predisposed to develop Alzheimer’s earlier in life, making them a high-risk group. The study underscores the need for gender-sensitive approaches in research and treatment strategies.
Professor Elizabeth Head, a co-author of the study, emphasized that if women are already at a more advanced stage at the time of diagnosis, it could significantly impact how interventions are timed and how the results of clinical trials are interpreted. She added that the research may provide broader insights into how sex differences affect Alzheimer’s in the general population, potentially leading to more personalized treatment plans.
The study calls for a greater focus on inclusive and sex-specific data in all future Alzheimer’s research and clinical trials to avoid overlooking critical biological differences that could affect treatment outcomes.
Disclaimer: This news article is for informational purposes only and does not constitute medical advice. Consult a healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Reference:
Andrews, E., et al. (2023). Sex differences in Alzheimer’s disease-related neuropathology in Down syndrome. Alzheimer’s & Dementia.
https://www.daijiworld.com/news/newsDisplay?newsID=1289137
